<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547312</url>
  </required_header>
  <id_info>
    <org_study_id>5172-022</org_study_id>
    <secondary_id>2011-004978-29</secondary_id>
    <nct_id>NCT01547312</nct_id>
  </id_info>
  <brief_title>Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)</brief_title>
  <official_title>A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is divided into 2 segments, and proposes to qualify fine needle aspiration (FNA)
      as a platform to evaluate the hepatic pharmacokinetics of low and high oral doses of
      Grazoprevir (MK-5172) in non-cirrhotic participants chronically infected with hepatitis C
      virus (HCV). The first segment, is a procedural pilot conducted prior to the main study, that
      is aimed at ensuring optimal execution of the FNA procedure. During the procedural pilot,
      core needle biopsy (CNB) will be performed on participants as part of their standard of care,
      but no study drugs will be administered, nor will any procedures other than FNA be conducted.
      The second segment, the main study, is designed to evaluate the feasibility of measuring
      Grazoprevir by FNA. During the main study, drugs will be administered, and other additional
      procedures will be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.</measure>
    <time_frame>Days 7-12.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Pt.1: 800 mg Grazoprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg Grazoprevir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Procedural Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimization of FNA procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-Interferon</intervention_name>
    <description>Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Samples from FNA</intervention_name>
    <description>Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt.1: 800 mg Grazoprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Samples from CNB</intervention_name>
    <description>Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt.1: 800 mg Grazoprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Samples</intervention_name>
    <description>Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt.1: 800 mg Grazoprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800 mg Grazoprevir</intervention_name>
    <description>800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.</description>
    <arm_group_label>Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>Main Pt.1: 800 mg Grazoprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg Grazoprevir</intervention_name>
    <description>100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.</description>
    <arm_group_label>Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver samples from CNB and FNA</intervention_name>
    <description>Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.</description>
    <arm_group_label>Procedural Pilot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has chronic compensated HCV infection.

          -  No contraindications to CNB or FNA procedures.

          -  Pilot study only: All comers with chronic HCV already scheduled to undergo CNB for
             fibrosis staging.

          -  Pilot study only: Requires a diagnostic liver biopsy to monitor progression of liver
             disease.

          -  Pilot study only: Does not have cirrhosis.

          -  Main study only: Males or non-pregnant and postmenopausal females willing to use
             medically acceptable contraception during, and for 6 months or longer after study.

          -  Main study only: Body mass index of 18.5 - 32.0 kg/m^2.

          -  Main study only: Can avoid aspirin, anticoagulants, and non steroidal inflammatory
             agents.

          -  Main study only: Has undergone prior treatment or is treatment naive for chronic HCV
             infection.

        Exclusion Criteria for Main study only:

          -  History of any of the following: stroke, chronic seizures, major neurological
             disorders, gastric bypass surgery or bowel resection.

          -  No viral response to prior interferon based therapy.

          -  Prior treatment for HCV with an NS3/4A protease inhibitor.

          -  History of either clinically significant, uncontrolled endocrine, gastrointestinal,
             cardiovascular, hematological, immunological, renal, respiratory, or genitourinary
             abnormalities/diseases.

          -  History of neoplastic or myeloproliferative disease.

          -  Has any of the following : cirrhosis, decompensated liver disease, or other advanced
             liver disease, hepatocellular carcinoma, infection with human immunodeficiency virus
             (HIV), or hepatitis B.

          -  Evidence of high grade bridging fibrosis from prior liver biopsy or chronic hepatitis
             not caused by HCV.

          -  History of illicit drug use or alcohol abuse.

          -  Had surgery, donated at least one unit of blood, or participated in any other
             investigational study within 4 weeks prior to screening visit.

          -  History of multiple and/or severe allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

